Meet Samuel – Your Personal Investing Prophet
- Start a conversation with TipRanks’ trusted, data-backed investment intelligence
- Ask Samuel about stocks, your portfolio, or the market and get instant, personalized insights in seconds
Cyclopharm Limited ( (AU:CYC) ) has provided an update.
Cyclopharm Limited has signed a multi-site agreement with Northwestern Medicine, a leading academic health system based in Chicago, to install Technegas equipment initially at Northwestern Memorial Hospital with the potential to expand to six additional sites across the network. The deal establishes a crucial foothold in one of the largest U.S. healthcare markets, supports Cyclopharm’s strategy of using top-tier academic centres as reference sites, and adds to commercial momentum following a recent 11-site agreement with the University of Pennsylvania Health System, underpinning a scalable, recurring revenue model in the United States.
The most recent analyst rating on (AU:CYC) stock is a Sell with a A$0.68 price target. To see the full list of analyst forecasts on Cyclopharm Limited stock, see the AU:CYC Stock Forecast page.
More about Cyclopharm Limited
Cyclopharm Limited is an ASX-listed radiopharmaceutical company that serves the global medical community, supplying nuclear medicine clinicians with products aimed at improving patient outcomes. Its core product, Technegas, is used for functional lung ventilation imaging and has applications beyond pulmonary embolism, including COPD, asthma, pulmonary hypertension and certain lung cancer-related interventions.
Average Trading Volume: 144,075
Technical Sentiment Signal: Sell
Current Market Cap: A$86.98M
Learn more about CYC stock on TipRanks’ Stock Analysis page.